astragalin
(Synonyms: 紫云英苷; Astragaline; 3-Glucosylkaempferol; Kaempferol 3-β-D-glucopyranoside) 目录号 : GN10561
Astragalin是一种具有强抗氧化和抗炎活性的天然黄酮类化合物，在多种疾病（包括癌症和心血管疾病）中显示出潜在的治疗应用价值。
Cas No.:480-10-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Astragalin is a natural flavonoid compound with strong antioxidant and anti-inflammatory activities and has shown potential therapeutic applications in various diseases, including cancer and cardiovascular diseases[1]. Astragalin is extracted from plants such as Mongolian milkvetch (Astragalus membranaceus) and sumac (Rhus chinensis)[2]. In cancer research, Astragalin has been reported to inhibit the proliferation of cancer cells and induce apoptosis[3]. Astragalin also protects the cardiovascular system by reducing oxidative stress and inflammation[4].
In vitro, Astragalin (0–100µM) treatment of human colorectal epithelial cells (HCT-116 and HT-29) significantly inhibited cell proliferation. Pre-treatment with Astragalin significantly reduced the mRNA expression levels of tumor necrosis factor-α (TNF-α)-induced interleukin-6 (IL-6), IL-8, and TNF-α. Additionally, Astragalin inhibited the phosphorylation and degradation of IκBα induced by TNF-α and reduced the DNA-binding activity of NF-κB[5]. Astragalin (1–20µM) treatment of human bronchial epithelial cells (BEAS-2B) significantly inhibited the epithelial-mesenchymal transition (EMT) process induced by oxidative stress. Astragalin restored the reduced expression of E-cadherin induced by H₂O₂ and dose-dependently inhibited the expression of vimentin and the formation of autophagosomes[6].
In vivo, Astragalin (10, 20, 40mg/kg) was administered via intraperitoneal injection to APP/PS1 transgenic mice once daily for one month. Astragalin significantly improved cognitive dysfunction in APP/PS1 mice. Astragalin also alleviated neuronal damage in the hippocampus, reduced amyloid-β (Aβ) deposition and the number of senile plaques, and activated autophagy by promoting the expression of autophagy-related proteins (LC3B, Beclin-1, ATG5, ATG12, and LAMP-1). Furthermore, Astragalin inhibited the phosphorylation levels of PI3K/Akt-mTOR signaling pathway-related proteins, thereby exerting neuroprotective effects[7]. Astragalin (5, 10mg/kg/day) was administered orally to streptozotocin (STZ)-induced diabetic mice for 4 weeks. Astragalin significantly improved proteinuria and reduced serum creatinine levels in diabetic mice. Astragalin also alleviated renal pathological damage. Astragalin significantly inhibited the activity of aldose reductase (ALR2) in the kidneys, reduced oxidative stress, improved mitochondrial dysfunction, promoted mitochondrial biogenesis, maintained mitochondrial dynamic balance, and reduced renal cell apoptosis by activating the AMPK-dependent PGC1α pathway[8].
References:
[1] Chen J, Zhong K, Qin S, et al. Astragalin: a food-origin flavonoid with therapeutic effect for multiple diseases. Front Pharmacol. 2023 Oct 18;14:1265960.
[2] Riaz A, Rasul A, Hussain G, et al. Astragalin: A Bioactive Phytochemical with Potential Therapeutic Activities. Adv Pharmacol Sci. 2018 May 2;2018:9794625.
[3] Ruan J, Shi Z, Cao X, et al. Research Progress on Anti-Inflammatory Effects and Related Mechanisms of Astragalin. Int J Mol Sci. 2024 Apr 19;25(8):4476.
[4] Zhang Q, Yan Y. The role of natural flavonoids on neuroinflammation as a therapeutic target for Alzheimer's disease: a narrative review. Neural Regen Res. 2023 Dec;18(12):2582-2591.
[5] Han YM, Koh J, Kim JH, et al. Astragalin Inhibits Nuclear Factor-κB Signaling in Human Colonic Epithelial Cells and Attenuates Experimental Colitis in Mice. Gut Liver. 2021 Jan 15;15(1):100-108.
[6] Cho IH, Choi YJ, Gong JH, et al. Astragalin inhibits autophagy-associated airway epithelial fibrosis. Respir Res. 2015 Apr 21;16(1):51.
[7] Yang CZ, Wang SH, Zhang RH, et al. Neuroprotective effect of astragalin via activating PI3K/Akt-mTOR-mediated autophagy on APP/PS1 mice. Cell Death Discov. 2023 Jan 21;9(1):15.
[8] Sun MY, Ye HJ, Zheng C, et al. Astragalin ameliorates renal injury in diabetic mice by modulating mitochondrial quality control via AMPK-dependent PGC1α pathway. Acta Pharmacol Sin. 2023 Aug;44(8):1676-1686.
Astragalin是一种具有强抗氧化和抗炎活性的天然黄酮类化合物，在多种疾病（包括癌症和心血管疾病）中显示出潜在的治疗应用价值[1]。Astragalin是一种从植物如蒙古黄芪（Astragalus membranaceus）和漆树（Rhus chinensis）中提取的天然黄酮类化合物[2]。在癌症研究中，Astragalin被报道可以抑制癌细胞的增殖并诱导细胞凋亡[3]。Astragalin还通过减少氧化应激和炎症对心血管系统起到保护作用[4]。
在体外，Astragalin（0-100μM）处理人结肠上皮细胞（HCT-116和HT-29），显著抑制了细胞的增殖。Astragalin预处理显著降低了肿瘤坏死因子-α（TNF-α）诱导的白细胞介素-6（IL-6）、白细胞介素-8（IL-8）和TNF-α的mRNA表达水平。此外，Astragalin抑制了TNF-α诱导的IκBα的磷酸化和降解，并降低了NF-κB的DNA结合活性[5]。Astragalin（1-20μM）处理人支气管上皮细胞（BEAS-2B），显著抑制了氧化应激诱导的上皮-间充质转化（EMT）过程。Astragalin恢复了H₂O₂诱导的E-钙黏蛋白（E-cadherin）表达的降低，并剂量依赖性地抑制了波形蛋白（vimentin）的表达，并减少了自噬体的形成[6]。
在体内，Astragalin（10、20、40mg/kg）通过腹腔注射的方式对APP/PS1转基因小鼠进行治疗，每天一次，持续一个月。Astragalin显著改善了APP/PS1小鼠的认知功能障碍，Astragalin减轻了小鼠海马区的神经元损伤，降低了Aβ沉积和老年斑的数量，并通过激活自噬相关蛋白（LC3B、Beclin-1、ATG5、ATG12和LAMP-1）的表达，促进了自噬的启动、自噬体的形成和自噬溶酶体的降解，同时抑制了PI3K/Akt-mTOR信号通路相关蛋白的磷酸化水平，从而发挥了神经保护作用[7]。Astragalin（5、10mg/kg/day）通过口服方式对链脲佐菌素（STZ）诱导的糖尿病小鼠进行治疗，持续4周。Astragalin显著改善了糖尿病小鼠的蛋白尿，降低了血清肌酐水平，减轻了肾脏病理损伤。Astragalin显著抑制了肾脏中醛糖还原酶（ALR2）的活性，降低了氧化应激水平，改善了线粒体功能障碍，促进了线粒体生物合成，维持了线粒体动态平衡，并通过激活AMPK依赖的PGC1α通路减少了肾脏细胞凋亡[8]。
| Cell experiment [1]: | |
Cell lines | BEAS-2B cells |
Preparation Method | BEAS-2B cells were seeded into 6-well plates at a density of 5 × 104 cells per well and cultured in HEPES-buffered M199 medium containing 10% FBS and other supplements for 24 hours. The cells were then pretreated with different concentrations (1, 5, 10, and 20μM) of Astragalin for 1 hour before being stimulated with 20μM H₂O₂ for up to 72 hours. |
Reaction Conditions | 1, 5, 10, and 20μM Astragalin; 20μM H₂O₂; 72 hours |
Applications | Astragalin significantly restored the expression of E-cadherin and inhibited the induction of vimentin in H₂O₂-treated BEAS-2B cells, indicating its ability to attenuate EMT. Astragalin blocked the induction of autophagy-related proteins beclin-1 and LC3A/B and reduced autophagosome formation. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | Six-week-old male C57BL/6J mice were used. Diabetes was induced by intraperitoneal injection of streptozotocin (STZ, 100mg/kg/day) for two consecutive days. Seven days after injection, mice with random blood glucose ≥16.7mmol/L were randomly divided into groups and treated with Astragalin (5 and 10mg/kg/day) by oral gavage for 4 weeks. At the end of the experiment, blood and kidney tissues were collected for analysis. |
Dosage form | 5 and 10mg/kg/day for 4 weeks; p.o. |
Applications | Astragalin significantly improved renal function by reducing proteinuria, lowering serum creatinine levels, and improving kidney pathological damage in diabetic mice. It also inhibited aldose reductase activity, reduced oxidative stress, improved mitochondrial dysfunction, and regulated mitochondrial dynamics by activating the AMPK/PGC1α pathway. |
References: | |
| Cas No. | 480-10-4 | SDF | |
| 别名 | 紫云英苷; Astragaline; 3-Glucosylkaempferol; Kaempferol 3-β-D-glucopyranoside | ||
| 化学名 | 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one | ||
| Canonical SMILES | C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O | ||
| 分子式 | C21H20O11 | 分子量 | 448.38 |
| 溶解度 | ≥ 44.8mg/mL in DMSO | 储存条件 | Store at 2-8°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2303 mL | 11.1513 mL | 22.3025 mL |
| 5 mM | 0.4461 mL | 2.2303 mL | 4.4605 mL |
| 10 mM | 0.223 mL | 1.1151 mL | 2.2303 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet